NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Halo Biosciences

Halo Biosciences

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://halobiosciences.com/

Last Round

Grant

May 15, 2024

Total Funding Raised

$1.04M

Company Overview

Halo Biosciences is a clinical-stage biopharmaceutical company that develops disease-modifying therapies by targeting the extracellular matrix to treat inflammatory and fibrotic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryclinical-stage biotechpulmonary hypertensioninterstitial lung diseasePH-ILDhyaluronanextracellular matrixECMsmall molecule therapyfibrotic diseasedrug developmentclinical trialsbiotech startuptherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Halo Biosciences Comparables

Compare Halo Biosciences with similar companies based on industry and business-model similarity.

Halo Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pliant Therapeutics
73%
Roivant Sciences
72%
Mediar Therapeutics
71%

Halo Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 15, 2024
AcceleratorNov 8, 2019

Key People

Founding team and executive leadership

Anissa Kalinowski

CEO, Cofounder

Founding Team

Kristen Lorentz

Consulting COO

Executive Team

Halo Biosciences Investors

Notable investors and investment history

Halo Biosciences investors
InvestorRounds
National Heart, Lung, and Blood InstituteGrant
QB3Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 5, 2026

    Monthly visitors increased 200% MoM, reaching 1.1K.

  • Jan 20, 2026

    Monthly visitors increased 1042% MoM, from 31 to 354.

Halo Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Halo Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Halo Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range9
Year Founded2019
Last FundingMay 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.